Answers are grounded in this paper and cite their sources.
Over the years, the overall survival of older patients diagnosed with acute myeloid leukemia (AML) has not significantly increased. Although standard cytotoxic therapies that rapidly eliminate dividing myeloblasts are used to induce remission, relapse can occur due to surviving therapy-resistant leukemic stem cells (LSCs). Hence, anti-LSC strategies have become a key target to cure AML. We have recently shown that previously approved cardiac glycosides and glucocorticoids target LSC-enriched CD34
No takes yet. Share an insight, caveat, or question.
Brunetti et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: